Organization
U.S. Senate Special Committee on Aging
Senate committee that held the April 2016 Valeant hearing.
Connections 2
involved in
- Senate hearing on Valeant, April 2016 held the hearing; its chair gave these figures Primary record 1
part of
- U.S. Congress Primary record 1
Proof 1 source
-
Valeant Pharmaceuticals' Business Model: The Repercussions for Patients and the Health Care System, hearing, S. Hrg. 114-846, U.S. Senate Special Committee on Aging, 27 Apr 2016.
Primary record
The price increases for the other three drugs were even worse: 720 percent for Isuprel, almost 3,200 percent for Syprine, and nearly 6,000 percent for Cuprimine.
HEARING BEFORE THE SPECIAL COMMITTEE ON AGING UNITED STATES SENATE ONE HUNDRED FOURTEENTH CONGRESS
Page history 1 change
- Add 55 stories, each checked against its sources96e92fe6
Something wrong or missing? Tell us, with a source, or edit this page.